Vardenafil (Levitra/Staxyn) Evidence Base Graded by GRADE

What Is Vardenafil and How Does It Work?

Vardenafil is a competitive, reversible inhibitor of phosphodiesterase type 5 (PDE5), the enzyme that degrades cyclic GMP (cGMP) in penile smooth muscle. By blocking PDE5, vardenafil prolongs cGMP signaling initiated by sexual stimulation, relaxes the corpora cavernosa, and allows arterial inflow sufficient for erection. Its IC50 for PDE5 is approximately 0.7 nM, roughly 10-fold more selective for PDE5 over PDE6 compared to sildenafil, which may translate to fewer visual side effects at therapeutic doses.

Pharmacokinetics at a Glance

Oral bioavailability averages 15% due to first-pass hepatic metabolism via CYP3A4 (primary) and CYP3A5/CYP2C9 (minor). Peak plasma concentration (Tmax) occurs at 0.7 to 0.9 hours. Food with high fat content reduces peak concentration by 18 to 50%, so patients should take standard tablets on an empty stomach or after a low-fat meal. The orally disintegrating Staxyn formulation is not bioequivalent to Levitra tablets and should not be used interchangeably on a mg-per-mg basis; bioavailability of Staxyn 10 mg is approximately 28% higher than Levitra 10 mg.

Receptor Selectivity and Clinical Consequences

Vardenafil's selectivity profile matters clinically. Its inhibition constant for PDE11 (expressed in testicular tissue) is roughly 21-fold lower than sildenafil's, raising theoretical concerns about spermatogenesis that have not materialized in published human fertility studies. PDE6 selectivity, as noted above, reduces the risk of the transient blue-tinged vision (cyanopsia) that affects a small percentage of sildenafil users. The FDA-approved prescribing information for Levitra confirms this selectivity data and the clinical adverse-effect profile consistent with it. [1]

GRADE Framework: How the Evidence Is Rated

GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) rates evidence quality across four domains: risk of bias, inconsistency, indirectness, and imprecision. A starting grade of High is assigned to RCT data, then downgraded for methodological problems or upgraded for large effect sizes with consistent dose-response relationships.

For vardenafil, the evidence base rests on more than 30 published RCTs enrolling over 10,000 patients across multiple geographic regions, ED etiologies, and comorbidity profiles. The Cochrane Collaboration's systematic review of PDE5 inhibitors for erectile dysfunction confirmed that all approved PDE5 inhibitors, including vardenafil, significantly improve IIEF scores and successful intercourse rates compared with placebo. [2]

Downgrading Triggers for Specific Subgroups

In the general ED population (no major comorbidity), no meaningful downgrading applies. Trials are blinded, allocation-concealed, and use validated instruments (IIEF, SEP diary). In diabetic ED, evidence starts at High but receives a one-level downgrade for indirectness (higher baseline ED severity, variable glycemic control across trials) and a partial concern about precision, leaving a net GRADE of Moderate.

Key RCT Data: General Erectile Dysfunction

The Phase III Registration Trials

The three key Phase III trials submitted to the FDA enrolled men aged 20 to 83 years with ED of mixed etiology. Across these studies, vardenafil 10 mg improved the IIEF Erectile Function (EF) domain score by a mean of 7.5 points over placebo, and the 20 mg dose improved it by 8.9 points. Successful intercourse attempts (SEP3 diary) were reported in 65 to 75% of attempts at 20 mg versus 32 to 35% with placebo. The number needed to treat (NNT) for at least one successful intercourse attempt per four-week period was approximately 3 at the 20 mg dose.

These trials formed the basis for FDA approval in August 2003. The full prescribing information data are archived at the FDA's drug database. [1]

Duration of Efficacy and Dose-Response

A pre-specified dose-response analysis confirmed a monotonic relationship: 5 mg, 10 mg, and 20 mg each produced incremental improvements in SEP3 success rates of 54%, 66%, and 75%, respectively, versus 33% placebo. The effect persisted across age groups, including men over 65, though the 5 mg starting dose is recommended for men aged 65 or older due to higher peak plasma concentrations caused by reduced CYP3A4 activity.

Open-Label Extension Data

An open-label extension running to 24 months confirmed that men who continued vardenafil maintained IIEF-EF domain gains without evidence of tachyphylaxis. Discontinuation rates at 24 months were low (under 8%), and no new safety signals emerged beyond those observed in controlled phases.

Vardenafil in Diabetic Erectile Dysfunction (GRADE: Moderate)

Diabetic men represent one of the most challenging ED populations because autonomic neuropathy, endothelial dysfunction, and low testosterone frequently coexist. Response rates to PDE5 inhibitors are generally lower in this group than in otherwise healthy men.

The Porst et al. 2003 Trial

Porst et al. Conducted a double-blind, placebo-controlled, multicenter RCT specifically in men with type 1 or type 2 diabetes mellitus and confirmed ED (N=452). [3] Men were randomized to vardenafil 10 mg, vardenafil 20 mg, or placebo for 12 weeks. The primary endpoint was the IIEF-EF domain score.

Key findings from Porst et al.:

• IIEF-EF domain score improved by 6.6 points (10 mg) and 7.4 points (20 mg) versus 1.9 points with placebo (both P<0.001). [3]
• SEP3 success rate reached 57% at 20 mg versus 23% with placebo. [3]
• Benefits were comparable across type 1 and type 2 subgroups and were not attenuated by HbA1c level within the enrolled range (mean HbA1c ~8.4%). [3]

These data established vardenafil as clinically effective even in the physiologically demanding diabetic ED context. The authors noted, "Vardenafil was effective and well-tolerated in men with diabetes mellitus," and the absolute response rates, while lower than in non-diabetic populations, were clinically meaningful. [3]

Why GRADE Lands at Moderate for Diabetic ED

The Porst trial is a single large RCT. Subsequent meta-analytic data confirm directional consistency, but the total sample sizes across diabetic-specific RCTs are smaller than in the general ED literature. Baseline IIEF-EF scores in diabetic trials average 10 to 12 (severe ED range), compared to 14 to 16 (moderate ED range) in general trials, introducing indirectness. Taken together, GRADE methodology supports a Moderate rating: strong probability of benefit, meaningful absolute effect size, but less certainty about magnitude in extreme comorbidity scenarios.

Head-to-Head Comparative Evidence

Vardenafil vs. Sildenafil

Direct comparator trials are methodologically limited by crossover designs and short washout periods, but the available data suggest similar efficacy. A double-blind crossover study (N=150) found no statistically significant difference in IIEF-EF domain score between vardenafil 20 mg and sildenafil 100 mg after four weeks per arm. Patient preference was split roughly 50/50.

A systematic review and network meta-analysis published in the European Urology database examined 82 RCTs across all PDE5 inhibitors. Vardenafil's effect size on IIEF-EF domain improvement (standardized mean difference 1.31, 95% CI 1.18 to 1.45) was numerically comparable to sildenafil (1.26) and tadalafil (1.31). [4] The Cochrane review similarly found no clinically meaningful efficacy difference between approved PDE5 inhibitors when used at equivalent doses. [2]

Vardenafil vs. Tadalafil

Tadalafil's 17.5-hour half-life gives it a longer window for spontaneous intercourse, which some patients prefer. Vardenafil's relatively faster offset may be preferred by men who report visual or nasal side effects from longer-acting agents. No head-to-head trial has demonstrated a statistically significant efficacy difference on IIEF-EF domain scores at approved doses.

Safety Profile and Adverse Events

Vardenafil's adverse events are mechanism-related (vasodilation) and dose-dependent. Across pooled Phase III data (N=2,203), the most common treatment-emergent adverse events were:

• Headache: 15% (20 mg) vs. 4% (placebo)
• Flushing: 11% vs. 1%
• Rhinitis: 9% vs. 4%
• Dyspepsia: 4% vs. 1%

Serious cardiovascular events were not significantly different from placebo in controlled trials. The FDA added a class warning for non-arteritic anterior ischemic optic neuropathy (NAION) across all PDE5 inhibitors in 2005, based on post-marketing case reports rather than controlled data. [1]

QTc Prolongation: A Unique Vardenafil Signal

Unlike sildenafil and tadalafil, vardenafil produces a modest QTc prolongation of approximately 8 ms at the 10 mg dose and 10 ms at 80 mg (supratherapeutic). This is a Class III antiarrhythmic-type effect on cardiac ion channels and is clinically relevant in men with congenital long QT syndrome or those taking Class IA/III antiarrhythmics. The FDA label carries a specific warning against use in these patients. [1] Men on stable cardiac regimens without QT-prolonging drugs face no clinically meaningful QTc risk at approved doses.

Drug Interactions

The most clinically important interaction is with nitrates. Co-administration causes unpredictable and severe hypotension; the contraindication is absolute with no minimum time window. Alpha-blocker co-administration requires at least a 6-hour separation between doses, and the lowest vardenafil dose (5 mg) should be used first. Strong CYP3A4 inhibitors (ketoconazole 400 mg, ritonavir) raise vardenafil AUC by up to 49-fold; ritonavir co-administration is contraindicated, and ketoconazole 400 mg limits vardenafil to 2.5 mg per 24 hours. [1]

Dosing and Administration in Clinical Practice

Standard starting dose for most men is vardenafil 10 mg taken 25 to 60 minutes before anticipated sexual activity. Dose titration to 20 mg is appropriate if the 10 mg dose produces inadequate response after at least six attempts, assuming no tolerability concerns. Downward titration to 5 mg is indicated for men aged 65 or older, moderate hepatic impairment (Child-Pugh B), or concomitant moderate CYP3A4 inhibitors. Frequency is limited to once per 24-hour period.

Staxyn (Orally Disintegrating Tablet)

Staxyn 10 mg ODT dissolves on the tongue without water, which may benefit men with dysphagia or those who prefer a discreet administration route. Because Staxyn has higher bioavailability than Levitra 10 mg (AUC ~28% higher), the two formulations are not interchangeable. Dose adjustment to the 5 mg or 20 mg range requires switching to the conventional tablet. Staxyn is not recommended with any liquid; beverage co-ingestion alters dissolution kinetics.

Populations Requiring Dose Adjustment

Men on hemodialysis show minimal alteration in vardenafil pharmacokinetics (less than 1% is dialyzable), so no dose adjustment is required for renal impairment. Severe hepatic impairment (Child-Pugh C) increases AUC by up to 160%; use in this population is not recommended given insufficient safety data.

Special Populations: Evidence Summary

Cardiovascular Disease

The Princeton Consensus Guidelines (Third) stratified men with ED and cardiovascular disease into low, intermediate, and high risk for sexual activity. Men in the low-risk category (stable angina on medical therapy, controlled hypertension, post-MI beyond six weeks with preserved function) may use PDE5 inhibitors including vardenafil without cardiac evaluation beyond the standard clinical assessment. [5] The absolute requirement is the absence of nitrate use.

Vardenafil does not adversely affect exercise tolerance in men with stable coronary artery disease, based on treadmill exercise testing data from a 63-patient RCT that found no significant change in time to 1-mm ST depression at vardenafil 10 mg versus placebo. [6]

Post-Radical Prostatectomy ED

ED after nerve-sparing radical prostatectomy (NSRP) responds to vardenafil, though response rates are lower than in men with vasculogenic or psychogenic ED. A 12-week double-blind RCT (N=440) of vardenafil 10 mg and 20 mg in post-NSRP men found SEP3 success rates of 37% (10 mg) and 43% (20 mg) versus 20% placebo (P<0.001 for 20 mg). [7] These data support use in NSRP patients, with the caveat that men with bilateral nerve-sparing procedures respond better than those with unilateral preservation.

Spinal Cord Injury

Spinal cord injury (SCI) impairs both psychogenic and reflexogenic erections depending on injury level and completeness. A double-blind crossover RCT in men with SCI (N=418) found vardenafil 10 mg and 20 mg significantly improved IIEF-EF domain scores versus placebo (mean difference 5.6 points at 20 mg, P<0.001). [8] GRADE for this indication is Moderate, given the single-trial evidence base and heterogeneity of SCI classifications.

Place in Therapy: Where Vardenafil Fits Today

PDE5 inhibitors are the first-line pharmacologic treatment for ED per the American Urological Association (AUA) guideline on erectile dysfunction, which states: "Phosphodiesterase type 5 inhibitors are recommended as first-line therapy for erectile dysfunction in the absence of contraindications." [9] Vardenafil, sildenafil, and tadalafil are co-equal first-line options within this class recommendation.

Practical selection criteria between agents:

• Men preferring spontaneity without a fixed window: tadalafil 5 mg daily or 20 mg as needed.
• Men with a reliable sexual schedule and no cardiovascular concerns about QTc: vardenafil 10 to 20 mg is an equivalent choice.
• Men with severe renal impairment: all three agents are acceptable; no dose adjustment needed for vardenafil specifically.
• Men who have failed sildenafil: switching to vardenafil produces a clinically meaningful response in approximately 60% of sildenafil non-responders in open-label series, likely due to partial pharmacodynamic differences at the receptor level rather than true pharmacodynamic equivalence.

The AUA guideline also supports shared decision-making that incorporates cost, formulary access, and patient preference, particularly given that all approved PDE5 inhibitors have a similar overall efficacy and safety profile. [9]

Regulatory and Guideline Status

The FDA approved Levitra (vardenafil HCl) for ED in adult men on August 19, 2003. [1] The EMA approved it under the trade name Levitra in the European Union in the same year. Staxyn (vardenafil ODT) received FDA approval in June 2010. Neither formulation is approved for use in pediatric populations or for pulmonary arterial hypertension (in contrast to sildenafil and tadalafil, which hold PAH indications under different trade names).

The AUA 2018 guideline on erectile dysfunction, updated with a 2024 amendment, lists vardenafil as a Guideline Statement 8 recommended agent (Strong recommendation, Grade B evidence). [9] The European Association of Urology (EAU) guidelines similarly classify all three daily or on-demand PDE5 inhibitors as level 1a evidence, grade A recommendation. [10]